Biotech start-up Synthace raises £7.3m Series A to “enable faster breakthroughs”
Based in London, the company behind the Antha open-source operating system counts GlaxoSmithKline, Merck and Dow among its clients
Synthace, the biotech start-up behind the Antha platform, has raised £7.3m Series A in a funding round to “enable faster breakthroughs” in the medical sector.
White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital participated in the round – alongside existing shareholders Sofinnova Partners, SOSV and Bioeconomy Capital.
Designed to make reproducible and scalable workflows that can be readily edited and shared, and easily automated on labs’ existing equipment, Antha helps users (mainly researchers) “aim higher and achieve better results”.
Based in London, Synthace counts GlaxoSmithKline, Merck and Dow among its clients and will use this latest injection of cash to expand its rapidly growing eco-system of biologists, lab instrumentation manufacturers, reagent and consumable suppliers, bio-design and analysis software developers and cloud providers.
In 2016, the World Economic Forum included Synthace in its selection of the world’s 30 most promising ‘Technology Pioneers’ that are helping shape the Fourth Industrial Revolution – which largely relates to how tech is disrupting and improving how we live our everyday lives.
Tim Fell, Synthace CEO, said:
“A sustainable future simply must include a better ability to engineer biology.
“Our need to heal, feed, fuel and manufacture for a growing population can be met by unlocking the near infinite power of biology but only by bringing software abstraction and more automation to biological R&D and manufacturing, and by enabling biologists to build atop their collective work.
“That is what the Antha platform does, and why we are so passionate about realizing its potential.”
Isabel Fox, head of venture at White Cloud Capital, said:
“Synthace is transforming the way biotechnology is developed and the $170bn global life science R&D budget spent. The traction the Company has achieved with pharmaceutical, agritech and industrial biotechnology customers shows the cross-sector applicability of Antha.
“We are excited to support the company in bringing this technology to the immense market of any researcher or organisation developing products or services that incorporate biology.”